Flagship Pioneering’s new spinout wants to stop disease before it starts

Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define ‘Biostages’ of Disease

Etiome’s precision medicine approach introduces a temporal component to treating disease — drugs developed specifically to treat disease at particular points in time even before symptoms show. The Flagship Pioneering startup’s approach offers the potential to prevent disease; in cases where disease is already present, Etiome aims to halt or even reverse it. The post Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define ‘Bios…

Flagship Pioneering’s new spinout wants to stop disease before it starts

A new Cambridge biotech is creating a roadmap to expand preventive health to a broader range of diseases, treating patients before they become irreversibly ill.

Etiome, a new Flagship startup, looks to catch disease before it strikes

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene beforehand with a targeted medication.

Avidicure's $50M seed round; Flagship's new AI company that detects disease

Plus, news about Novo Holdings, Bioxodes and Tempus AI: Dutch biotech raises $50M in seed funding: Avidicure, which is developing avidity engineered antibodies for cancer, said it plans to use the funding to move its ...

Avidicure Raises $50M in Seed Financing

Avidicure, an Amsterdam, The Netherlands-based biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology, raised $50m in seed financing. The round was led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures. Led by Arthur Lahr, Chief Executive Officer, Avidicure is developing […] The post Avidicure Raises $50M in …